Clinical Trial Highlights

• A Comparison of Clinical Outcomes following on-versus off-CABG Shows Mixed Results
• HPS2-THRIVE: Niacin Fails to Show Benefit in Patients at High Risk of Vascular Events
• High-Dose Rosuvastatin Reduces Contrast-Induced Nephropathy
• The TACT Trial: Provocative Results for High-Dose Vitamins and Chelation Therapy
• Cangrelor Offers Protective Benefits in PCI Patients
• BNP Screening, Targeted Care Reduce Heart Failure in At-Risk Patients
• PDE-5 Inhibition Has No Effect on Measures of Heart Failure
• First Clinical Evidence Offered That Inhibiting P-Selectin May Limit Myocardial Damage during PCI
• Eplerenone Post Myocardial Infarction Plus Standard Treatment May Prevent Adverse Cardiovascular Outcomes
• Ranolazine Provides Benefit over Placebo for T2DM Patients with Angina
• Digoxin Reduces 30-Day Hospital Admission in Older Ambulatory Patients with Heart Failure
• Early Fibrinolysis as Effective as Primary PCI When Reperfusion Delay is Long
• New SAPIEN XT System is Noninferior to and Safer Than Old SAPIEN System
• MASS COM Trial: Nonemergency PCI Safe without on-Site Surgery Capability
• ASTRONAUT Study: Aliskiren Does Not Improve Postdischarge Outcomes in Patients Hospitalized for Chronic Heart Failure